Microbubbles in macrocysts – Contrast-enhanced ultrasound assisted sclerosant therapy of a congenital macrocystic lymphangioma: a case report

• Main Authors: Carlos Menendez-Castro, Maren Zapke, Fabian Fahlbusch, Heiko von Goessel, Wolfgang Rascher, Jörg Jüngert
• Format: Article
• Language: English
• Published: BMC 2017-07-01
• Series: BMC Medical Imaging
• Subjects: Contrast agent-enhanced ultrasound; CEUS; Congenital cystic lymphangioma; SonoVue®; Sclerosant therapy; OK-432
• Online Access: http://link.springer.com/article/10.1186/s12880-017-0213-9

Abstract Background Congenital cystic lymphangiomas are benign malformations due to a developmental disorder of lymphatic vessels. Besides surgical excision, sclerosant therapy of these lesions by intracavitary injection of OK-432 (Picibanil®), a lyophilized mixture of group A Streptococcus pyogenes, is a common therapeutical option. For an appropriate application of OK-432, a detailed knowledge about the structure and composition of the congenital cystic lymphangioma is essential. SonoVue® is a commercially available contrast agent commonly used in sonography by intravenous and intracavitary application. Case presentation Here we report the case of 2 month old male patient with a large thoracic congenital cystic lymphangioma. Preinterventional imaging of the malformation was performed by contrast-enhanced ultrasound after intracavitary application of SonoVue® immediately followed by a successful sclerotherapy with OK-432. Conclusions Contrast agent-enhanced ultrasound imaging offers a valuable option to preinterventionally clarify the anatomic specifications of a congenital cystic lymphangioma in more detail than by single conventional sonography. By the exact knowledge about the composition and especially about the intercystic communications of the lymphangioma sclerosant therapy becomes safer and more efficient.